| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 193.4 | 167.2 |
| Gross profit | 148.9 | 122.5 |
| Profit before tax | -7.9 | -30.0 |
| Net income | -10.4 | -37.3 |
| EPS (diluted, $ a share) | $-0.09 | $-0.33 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +15.7% |
|---|---|
| Gross margin | 77.0% |
| Operating margin | -3.2% |
10-Q filed with the SEC, NASDAQ: NVCR. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
NovoCure Ltd: key numbers
- Share price
- $11.30Close, Nov 16
- Market cap
- $1.32B
- Shares outstanding
- 116.92MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from NovoCure Ltd
All →NovoCure COO Mukund Paravasthu Sells $39.6K of Stock
Mukund Paravasthu, COO, sold 3,079 shares of NovoCure Ltd at $12.86 a share, worth $39.6K in total on Nov 9, 2026. Shares held after the trade: 69,753 (-4.2%).
- Value
- $39.6K
- Shares
- 3,079
- Price
- $12.86
- Role
- COO
- Holding change
- -4.2%
- Trade date
- Nov 9, 2026
NovoCure CFO Christoph Brackmann Sells $94.4K of Stock
Christoph Brackmann, CFO, sold 7,343 shares of NovoCure Ltd at $12.86 a share, worth $94.4K in total on Nov 9, 2026. Shares held after the trade: 175,499 (-4.0%).
- Value
- $94.4K
- Shares
- 7,343
- Price
- $12.86
- Role
- CFO
- Holding change
- -4.0%
- Trade date
- Nov 9, 2026
NovoCure Business Update
NovoCure received a Not Approvable Letter from the FDA regarding its Premarket Approval (PMA) application for Optune Mya for treating brain metastases from non-small cell lung cancer. The FDA cited uncertainty regarding the degree of clinical benefit rather than safety concerns, and the company plans to meet with the regulator to discuss potential paths forward without additional clinical studies.
NovoCure Financial Results
Novocure reported record third-quarter net revenues of $193.4 million, a 16% year-over-year increase driven by 19% growth in active patients. The company significantly narrowed its net loss to $10.4 million and raised its full-year 2026 revenue and adjusted EBITDA guidance based on strong commercial performance.
- Term
- Q3 2026
“Novocure’s strong third quarter performance was driven by continued growth in our Optune Gio business and our growing portfolio of products launching in new markets, resulting in a record number of active patients on our therapies.”
Frank Leonard, CEO, Novocure
“We achieved record-high quarterly net revenue and are well-positioned to achieve the commercial, clinical and financial goals we set out in January. Based on the results from this quarter, we have raised our financial guidance for 2026 and will continue to build on the strong progress we have made on our path to profitability.”
Frank Leonard, CEO, Novocure
NovoCure Regulatory Approval
NovoCure received approval from Japan's Ministry of Health, Labour and Welfare for its Optune Pax device to treat adult patients with unresectable locally advanced pancreatic cancer. The approval was based on Phase 3 PANOVA-3 trial results showing statistically significant improvement in median overall survival. This marks a major commercial milestone for the company in Japan, where pancreatic cancer is the fourth leading cause of cancer death.
- Counterparty
- Ministry of Health, Labour and Welfare (MHLW)